<DOC>
	<DOC>NCT02285777</DOC>
	<brief_summary>This is extension of the V102_16 study (NCT02140762). V102_16E1 is designed to assess the effectiveness of a 3-dose vaccination series of MenABCWY, administered according to 0, 2, 6 month schedule, against the same panel of endemic US N. meningitidis serogroup B strains, as measured by enc-hSBA assay. The subjects who completed the parent V102_16 study will be invited at the time of their last study visit to participate in this extension study.</brief_summary>
	<brief_title>Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adolescents who completed V102_16 study and received the study vaccines as assigned in the protocol (either two doses of the MenABCWY or one dose each of MenACWY and Placebo). Serious, acute, or chronic illnesses. Previous or suspected disease caused by N. meningitidis. History of any meningococcal vaccine administration other than vaccination given in the parent V102_16 protocol.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>